Escalante, Jacinta C.
HRN: 22-69-61 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
03/05/2023
METRONIDAZOLE 5MG/ML, 100ML (VIAL)
03/05/2023
03/12/2023
IV
500mg
Q8h
Cholecystolithiasis
Waiting Final Action
Indication: ProphylaxisEmpiric Type of Infection: Intra-abdominal Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes